Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy Adults

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 to 55 years
• All sexes
• Healthy volunteers accepted
• Adult

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

Official title: A Phase 1, Double-blind, Placebo-Controlled, First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses ofABBV-1162 in Healthy Subjects

Conditions

Healthy Volunteers

Being tested

ABBV-1162, Placebo

Keywords

Healthy Volunteers, ABBV-1162

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• ABBV-1162Drug

  Oral

• PlaceboDrug

  Oral

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Number of Participants Experiencing Adverse Events

   An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

   Measured: Up to approximately 31 days

2. Maximum Plasma Concentration (Cmax) of ABBV-1162

   Cmax of ABBV-1162

   Measured: Up to approximately 3 days

3. Time to Cmax (Tmax) of ABBV-1162

   Time to Cmax (Tmax) of ABBV-1162

   Measured: Up to approximately 3 days

4. Terminal Phase Elimination Rate Constant (Beta) of ABBV-1162

   Beta of ABBV-1162

   Measured: Up to approximately 3 days

5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-1162

   t1/2 of ABBV-1162

   Measured: Up to approximately 3 days

6. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-1162

   AUCt of ABBV-1162

   Measured: Up to approximately 3 days

7. AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-1162

   AUCinf of ABBV-1162

   Measured: Up to approximately 3 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted22 Sep 2026
2. Study start2 Nov 2026 (estimated)
3. Primary completionMay 2027 (estimated)
4. Study completionMay 2027 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Healthy VolunteersStudies of the same condition, open and under way.
• More trials run by AbbVieThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.